Recent studies in laboratory rodents have revealed that circadian oscillation in the physiologic functions affecting drug disposition underlies the dosing time-dependent change in pharmacokinetics. However, it is difficult to predict the circadian change in the drug pharmacokinetics in a diurnal human by using the data collected from nocturnal rodents. In this study, we used cynomolgus monkeys, diurnal active animals, to evaluate the relevance of intestinal expression of P-glycoprotein (P-gp) to the dosing time dependency of the pharmacokinetics of its substrates. The rhythmic phases of circadian gene expression in the suprachiasmatic nuclei (the mammalian circadian pacemaker) of cynomolgus monkeys were similar to those reported in nocturnal rodents. On the other hand, the expression of circadian clock genes in the intestinal epithelial cells of monkeys oscillated at opposite phases in rodents. The intestinal expression of P-gp in the small intestine of monkeys was also oscillated in a circadian time-dependent manner. Furthermore, the intestinal absorption of P-gp substrates (quinidine and etoposide) was substantially suppressed by administering the drugs at the times of day when P-gp levels were abundant. By contrast, there was no significant dosing time-dependent difference in the absorption of the non-P-gp substrate (acetaminophen). The oscillation in the intestinal expression of P-gp appears to affect the pharmacokinetics of its substrates. Identification of circadian factors affecting the drug disposition in laboratory monkeys may improve the predictive accuracy of pharmacokinetics in humans.
Introduction
Many biologic processes are subject to daily oscillations, and some of these are controlled by a self-sustained oscillation mechanism called the circadian clock. In mammals, the circadian clock system is hierarchically organized, such that the master clock in the suprachiasmatic nuclei (SCN) of the hypothalamus integrates environmental information and synchronizes the phases of oscillators in peripheral tissues (Inouye and Kawamura, 1979; Sakamoto et al., 1998) . Molecular studies of the circadian biologic clock system have revealed that oscillation in the transcription of specific clock genes plays a central role in the generation of circadian rhythms. Clock is the first clock gene identified in mammals (Vitaterna et al., 1994; Antoch et al., 1997; King et al., 1997) . The Clock gene encodes the transcription factor, CLOCK, dimerizing with BMAL1 to activate the transcription of Period (Per) and Cryptochrome (Cry) genes through E-box or E-box-like enhancer sequences (Gekakis et al., 1998) . Once PER and CRY proteins have reached a critical concentration, they attenuate CLOCK/BMAL1-mediated transactivation, thereby generating circadian oscillation in their own transcription (Kume et al., 1999) . In addition, CLOCK/BMAL1, PER, and CRY proteins also regulate the circadian expression of the orphan nuclear receptor REV-ERBa, which in turn represses the transcription of Bmal1 (Preitner et al., 2002) . The molecular oscillator regulates daily variations in output physiology through periodic activation/repression of clockcontrolled output genes Maemura et al., 2000; Cheng et al., 2002) . Proline-and acid-rich (PAR) basic leucine zipper (bZIP) proteins, hepatic leukemia factor (HLF), thyrotroph embryonic factor (TEF), and D-site binding protein (DBP) are examples of such output mediators because their expression is probably regulated by core oscillator components (Gachon et al., 2004) . The circadian-controlled output pathways include those that control the expression of many enzymes and regulators involved in xenobiotic detoxification (Gachon et al., 2006) .
Intestinal transporters mainly function for the absorption of nutrients as well as for the excretion of harmful substances, and they also act as barriers against the systemic exposure to xenobiotics. The xenobiotic transporter P-glycoprotein (P-gp), encoded by ATP-binding cassette transporter genes Abcb1, functions as an energy-dependent efflux pump by expelling dx.doi.org/10.1124/mol.114.096735. cytotoxic substances. In mammals, P-gps are expressed in the epithelial cells of several organs, including the liver, intestine, and kidney (Schinkel et al., 1994) , and thus contribute to the biliary, intestinal, and renal elimination of many drugs. Since drug transporters recognize a broad range of substances (Litman et al., 2001) , it is now well recognized that they can function as an intestinal barrier to limit oral drug absorption.
We previously demonstrated that the circadian clockcontrolled output pathways regulate the intestinal expression of P-gp in mice (Murakami et al., 2008) . The oscillation in the expression of P-gp caused the dosing time-dependent change in the intestinal absorption of digoxin, a typical substrate of P-gp. Although our previous findings suggest that the efflux pump function of P-gp also exhibited circadian oscillation in the small intestine of mice, it is difficult to predict the circadian change in the pharmacokinetics of P-gp substrates in diurnal humans by using the data collected from nocturnally active rodents. To address this problem, we used cynomolgus monkeys, diurnal animals, to investigate the temporal pattern in the intestinal expression of circadian clock genes and pharmacokineticrelated factors involving P-gp. The rhythmic patterns of clock genes and P-gp in monkeys were substantially different from those in mice. We therefore explored how the circadian oscillation in the intestinal expression of P-gp affected the pharmacokinetics of its typical substrate in monkeys.
Materials and Methods
Animals. Cynomolgus monkeys (4-7 years old, male) were purchased from Shin Nippon Biomedical Laboratories, Ltd. (Wakayama and Kagoshima, Japan). They were kept separately one per cage and maintained on 90-100 g of solid food (Oriental Yeast Co., Ltd., Tokyo, Japan) and about 30 g of fresh fruit once a day (fed from 8:30 to 10:00), with free access to water, under a stable temperature (24 6 2°C), stable humidity (50 6 20%), and a 12-hour light/dark cycle (7:00-19:00) cycle. Animals were painlessly killed under anesthesia at 9:00, 15:00, 21:00, or 3:00. All tissues were quickly removed and frozen in liquid N 2 and stored at 280°C. For the pharmacokinetic experiments, animals were deprived of food for 12 hours before the experiments. Quinidine, etoposide, and acetaminophen (Sigma-Aldrich, St. Louis, MO) were suspended in a mixture of 0.5% methylcellulose solution for oral administration at a dose of 2, 0.5, and 5 mg/kg each for the monkeys. The suspension was administered orally at two different dosing times: 9:00 or 21:00. Blood samples were collected at 0.25, 0.5, 1, 2, 4, 6, and 8 hours after administration. This study was approved by the Committee on the Care and Use of Laboratory Animals of NAS Laboratories Co., Ltd. (Chiba, Japan), TransGenic Inc. (Kobe, Japan), and Daiichi Sankyo Co., Ltd. (Tokyo, Japan).
Quantitative Reverse Transcription-Polymerase Chain Reaction Analysis. Total RNA was extracted from the SCN, liver, or epithelial cells of the small intestine using an RNAiso reagent (Takara Bio Inc., Shiga, Japan). Coronal brain slices (4 mm) were prepared, and the SCN was punched out from the brain slices. cDNA was prepared via reverse transcription of total RNA using a ReverTra Ace qPCR RT kit (Toyobo Co. Ltd., Osaka, Japan). Diluted cDNA samples were analyzed by real-time polymerase chain reaction (PCR). Real-time PCR was performed using THUNDERBIRD SYBR qPCR mix (Toyobo Co. Ltd.) and a 7500 real-time PCR system (Applied Biosystems, Foster City, CA). The reaction conditions were 95°C for 10 seconds, followed by 45 cycles at 95°C for 5 seconds, 57°C for 10 seconds, and 72°C for 10 seconds. The sequences of primer pairs are listed in Table 1 . Western Blotting. The liver and jejunal segments were homogenized in Krebs-Ringel buffer (128.9 mM NaCl, 4.2 mM KCl, 1.5 mM CaCl 2 , 22.4 mM NaHCO 3 , 1.2 mM KH 2 PO 4 , 1.3 mM MgSO 4 , and 10 mM D-glucose) containing proteinase inhibitors (100 M phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin, and 2 mg/ml aprotinin) on ice. After centrifugation at 8000g for 15 minutes, nuclear proteins were extracted from the obtained pellets using an NE-PER nuclear extraction kit (Thermo Scientific, Rockford, IL), and the supernatants were further centrifuged for 60 minutes at 105,000g. The supernatants were used as cytosolic fractions, and the obtained pellets were resuspended in a membrane preparation buffer (20 mM Mops-Tris, pH 7.0, 0.3 M sucrose, 5 mM EDTA, 100 M phenylmethylsulfonyl fluoride, 2 mg/ml leupeptin, and 2 mg/ml aprotinin). The resuspensions were centrifuged for 60 minutes at 105,000g, and the resulting pellets were resuspended in a membrane preparation buffer and used as cellular membrane fractions. Protein concentrations were determined using a detergent-compatible protein assay kit (Bio-Rad, Hercules, CA). Samples (10-mg protein) were separated on SDS-polyacrylamide gels and transferred to a polyvinylidene fluoride membrane. The proteins on the membrane were reacted with antibodies against P-gp (Dako A/S, Glostrup, Denmark), MRP2 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA), BCRP (Santa Cruz Biotechnology), CYP3A (Daiichi Pure Chemical Co. Ltd., Tokyo, Japan), PER2 (Santa Cruz Biotechnology), BMAL1 (Santa Cruz Biotechnology), HLF (Abnova, Taipei City, Taiwan), TEF (Abcam, Cambridge, UK), DBP (Aviva System Biology, San Diego, CA), E4BP4 (Santa Cruz Biotechnology), or ACTIN (Santa Cruz Biotechnology). Specific antigen-antibody complexes were visualized using horseradish peroxidase-conjugated secondary antibodies and Chemi-Lumi One (Nakalai Tesque Inc., Kyoto, Japan). The reactions of proteins on the membrane with primary antibodies were performed for 12 hours. This reaction time was determined by checking the linearity, which was addressed by loading various amounts of proteins. For the detection of BCRP, the molecular Each value represents the mean 6 S.E. of three monkeys. There were significant time-dependent variations in the mRNA levels of Per1, Per2, and Reverba in both tissues (P , 0.05, respectively). (C and D) Temporal profiles of mRNA levels of PAR bZIP transcription factors and E4bp4 in the liver (C) and small intestine (D) of monkeys. Levels of mRNA were normalized to the amount of actin mRNA. Each value represents the mean 6 S.E. of three monkeys. There were significant time-dependent variations in the mRNA levels of Hlf, Tef, Dbp, and E4bp4 in both tissues (P , 0.05, respectively).
Circadian Expression of the Intestinal P-gp in Monkeys weight was individually variable, probably due to structural modification. However, treatment of samples with N-glycosidase (Takara Co. Ltd., Otsu, Japan) could not address the individual variations. Thus, we detected BCRP using the hepatic and intestinal samples without N-glycosidase treatment.
Construction of Luciferase Reporter Vectors. The 59-flanking region of the cynomolgus monkeys Abcb1 gene [from 21912 to 21328 bp; 11 indicates the transcription start site] was amplified using Platinum PCR SuperMix High Fidelity (Invitrogen, Carlsbad, CA) using the forward primer 59-AGCCTCGAGTATACATTTACCCCAGATGGA-39 and reverse primer 59-ATCAGATCTCCAGGCATTTCAAATTCTTAC-39. The PCR products were purified and ligated into a pGL4.12 promoter vector (Promega, Madison, WI). The putative PAR bZip response element (PARRE) on a wild-type reporter vector (wild type::Luc) was mutated in combination with others using a QuickChange site-directed mutagenesis kit (Stratagene, San Diego, CA). The changed sequences were as follows: bp of 21628 to 21621 was changed from TTATGCAA to TGGTACCA.
Luciferase Reporter Assay. At 24 hours after transfection of Caco2 cells with reporters (0.1 mg each) and expression constructs (0.5 mg each), cells were harvested, and the cell lysate was analyzed using a dual-luciferase reporter assay system (Promega). The ratio of firefly luciferase activity (expressed from the reporter construct) to Renilla luciferase activity (expressed from pRL-TK) in each sample served as a measure of normalized luciferase activity. Expression constructs for HLF, TEF, DBP, and E4BP4 were constructed as previously described (Murakami et al., 2008) .
Measurement of Plasma Drug Concentration by Means of High-Performance Liquid Chromatography-Tandem Mass Spectrometry. Acetaminophen, quinidine, and etoposide in 20-liter aliquots of plasma were extracted with 20 liters of 50% acetonitrile and 200 liters of internal standard solution (1 ng/ml phenacetin in 75% acetonitrile and 25% methanol), and then the mixtures were filtered to remove precipitated protein. The liquid chromatography system was an ACQUITY (Waters, Milford, MA). The analytical column was an Acquity ultra-performance liquid chromatography ethylene bridged hybrid C 18 (1.7 m, 2.0 Â 50 mm for acetaminophen and quinidine) or an ACQUITY CSH fluoro-phenyl (1.7 m, 2.0 Â 50 mm for etoposide) column (Waters). Mass spectrometry experiments were conducted on an API-4000 instrument (AB Sciex, Foster City, CA) with positive ionization electrospray. The multiple reaction monitor was set at 324. 9-160.0, 606.3 ([M 1 18] 1 ) to 229.1, 152.2-110.0, and 180.2-110.1 mass-to-charge ratio (m/z) for quinidine, acetaminophen, etoposide, and phenacetin, respectively. Pharmacokinetic Analysis. The maximum peak plasma concentrations (C max ) were directly read from the plasma concentration time profiles of quinidine, etoposide, and acetaminophen. The area under the plasma concentration time curve (AUC 0-8 hours ) and elimination half-life (t 1/2 ) were determined by noncompartmental methods using Phoenix WinNonlin software (version 6.3; Certara, Princeton, NJ).
Statistical Analysis. The statistical analysis was performed using Statview 4.0 (Abacus, Berkeley, CA). The significance of the 24-hour variation in each parameter was tested by analysis of variance. The statistical significance of differences among groups was analyzed by analysis of variance and the Tukey multiple comparison test. A 5% level of probability was considered significant. Pharmacokinetic parameters in vivo were presented as mean 6 standard error. Statistical comparisons of these parameters were performed by means of a Student's t test. Values of P , 0.05 were considered to be significant.
Results
Rhythmic mRNA Expression of Circadian Clock Genes and Clock-Controlled Genes in the SCN, Liver, and Intestinal Epithelial Cells of Cynomolgus Monkeys. To explore the temporal expression profiles of circadian clock genes in the diurnal animals, we investigated the mRNA levels of clock genes and PAR bZIP transcription factors in the SCN, liver, and intestinal epithelial cells of cynomolgus monkeys. The mRNA levels of Per1, Per2, Rev-erba, and Bmal1 in the SCN of monkeys showed a significant circadian oscillation (P , 0.05, respectively) ( Fig. 1) . For Per1 and Per2, mRNA levels peaked at 9:00, whereas Rev-erba mRNA levels peaked at 3:00. Bmal1 mRNA oscillation was nearly antiphase to that of the Rev-erba mRNA rhythm, with peak levels from the late light phase (15:00) to the early dark phase (21:00). These clock gene expression patterns are similar to those reported previously in the SCN of mice (Bae et al., 2001; Preitner et al., 2002) .
Significant rhythmic mRNA expression of Per1, Per2, and Rev-erba was also detected in the liver and intestinal epithelial cells of monkeys (P , 0.05, respectively) (Fig. 2,  A and B) , but there was no significant time-dependent variation in the mRNA levels of Bmal1. The rhythmic phases of Per1, Per2, and Rev-erba were similar to those observed in the SCN (Fig. 1) . In addition to these clock genes, the mRNA levels of clock-controlled genes, Hlf, Tef, Dbp, and E4bp4 also showed significant circadian oscillation in both liver and intestinal epithelial cells (P , 0.05, respectively) (Fig. 2, C and D) . The maximum mRNA levels of Hlf, Tef, and Dbp were observed from the early light phase to the midphase. On the other hand, mRNA oscillation of E4bp4, a putative antagonist of PAR bZip transcription factors, was nearly antiphase to that of PAR bZip transcription factors, with peak levels from the late light phase to the early dark phase. Rhythmic Expression of Pharmacokinetic-Related Factors in the Liver and Intestinal Epithelial Cells of Cynomolgus Monkeys. Since the expression of circadian clock genes and clock-controlled genes showed an obvious circadian oscillation, we also explored the temporal expression profiles of pharmacokinetic-related factors in the liver and intestinal epithelial cells of cynomolgus monkeys. The results of Western blotting analysis revealed that the protein levels of P-gp, MRP2, BCRP, and CYP3A in the liver of monkeys did not show obvious circadian oscillation (Fig. 3A) . The expression of P-gp and MRP2 was grossly constant throughout the day, whereas the protein levels of BCRP and CYP3A exhibited large individual variations. By contrast, the intestinal expression of P-gp, MRP2, and BCRP showed an obvious circadian oscillation (Fig. 3B) . The protein levels of these transporters decreased at an early light phase and then increased from the midlight phase to the early dark phase. However, likewise in the liver, the intestinal expression of CYP3A exhibited large individual variations (Fig. 3) .
Transcriptional Regulation of the Cynomolgus Monkey Abcb1 Gene by PAR bZip Factors and E4BP4. In rodents, circadian oscillation in the intestinal expression of P-gp is controlled at the transcriptional level (Murakami et al., 2008) . The mRNA levels of Abcb1, encoding P-gp, oscillated significantly in both liver and intestinal epithelial cells of monkeys (P , 0.05, respectively) (Fig. 4A ), but the amplitude of Abcb1 mRNA oscillation in the intestinal cells was higher than that observed in the liver. In the 59-flanking region of the cynomolgus monkey, the Abcb1 gene contains nucleotide sequences showing homology with the PARRE located between bp 21628 and 21621, with respect to the transcription start site.
PAR bZIP transcription factors and E4bp4 regulate the circadian expression of their target genes by competing with each other for binding to PARREs (Mitsui et al., 2001 ). The protein levels of circadian clock genes and PAR bZIP transcription factors in the intestinal epithelial cells of monkeys showed an obvious circadian oscillation (Fig. 4B) . The oscillation of PER2, HLF, TEF, and DBP showed a higher level during the Circadian Expression of the Intestinal P-gp in Monkeys light phase than during dark phase. The E4BP4 protein showed a higher level around the early dark phase, and had a different oscillation pattern from that of PER2, HLF, TEF, and DBP. Compared with these circadian clock genes and clock-controlled genes, the protein levels of BMAL1 failed to show an obvious oscillation.
To explore the functional importance of PARRE in the cynomolgus monkey Abcb1 gene for its circadian expression, we performed a transient transcriptional assay using luciferase reporter vectors. As shown in Fig. 4C , cotransfection of wild-type PARRE reporter vectors (wild type::Luc) with HLF, TEF, and DBP caused an obvious increase in the transcriptional activity. The transactivation effects were dependent on PARRE because mutation of this sequence from TTATGCAA to TGGTACCA resulted in no significant response to these transcriptional factors. The transactivation of the Abcb1 gene by PAR bZIP transcription factors was also repressed by E4BP4 (Fig. 4D) . The results suggest that PAR bZIP transcription factors and E4bp4 regulate the transcription of the cynomolgus monkey Abcb1 gene.
Dosing Time-Dependent Changes in the Pharmacokinetics of Orally Administrated P-gp Substrates in Cynomolgus Monkeys. Since circadian expression of P-gp in the small intestine of mice is related to the temporal change in the intestinal absorption of its substrate (Murakami et al., 2008) , we explored whether the pharmacokinetics of P-gp's substrates also varied depending on its dosing time. After oral Fig. 5 . Influence of dosing time on plasma concentration profiles of quinidine (A), etoposide (B), and acetaminophen (C) in monkeys. Quinidine (2 mg/kg), etoposide (0.5 mg/kg), and acetaminophen (5 mg/kg) were orally administered at 9:00 or 21:00. The plasma concentration of each drug was analyzed by liquid chromatography-tandem mass spectrometry. administration of P-gp substrates, quinidine or etoposide, into the monkeys, the C max of both drugs showed obvious dosing time-dependent differences (Fig. 5, A and B) . In all of the animals investigated in this experiment, the maximum plasma concentrations of quinidine and etoposide after administration at 9:00 were higher than those after at 21:00. Consequently, the mean values of the C max ratio (9:00/21:00) of these two P-gp substrates reached almost 2.0 (Table 2) . AUC 0-8 hours of quinidine after administration at 9:00 was higher than that at 21:00 due to a higher C max , and the AUC 0-8 hours ratio (9:00/21:00) of quinidine was greater than 1.0 and showed a statistical significance of differences from that of acetaminophen ( Fig. 5C ; Table 2 ). About etoposide, the C max after administration at 9:00 was higher than that after 21:00 in all monkeys, but the AUC 0-8 hours after administration at 9:00 was higher than that at 21:00 in only one monkey. On the other hand, maximum plasma concentrations of the non-P-gp substrate acetaminophen failed to show an obvious dosing time-dependent difference ( Fig. 5C ; Table 2 ). The mean values of the C max ratio (9:00/21:00) of acetaminophen was nearly 1.0 (Table 2 ). The AUC 0-8 hours ratio (9:00/21:00) of acetaminophen was smaller than 1.0 ( Fig. 5C ; Table 2 ). These results suggest that circadian expression of P-gp in the small intestine of monkeys affects the pharmacokinetics of its substrate after oral administration.
Discussion
Most laboratory rodents are active at night, but monkeys and humans exhibit higher activity during the daytime. Although the fundamental mechanism of the circadian clock system is highly conserved beyond the species, the timekeeping system in nocturnal animals is not simply inverted relative to that in diurnal species (Smale et al., 2003) . Therefore, it is important to recognize the difference in the rhythmicity between diurnal and nocturnal animals. In this study, we found that the rhythmic phase of circadian gene expression in the SCN of cynomolgus monkeys was similar to that reported previously in nocturnal rodents (Kume et al., 1999; Smale et al., 2003) . However, the mRNA expression of circadian clock genes and clock-controlled genes in the peripheral tissues of monkeys oscillated at opposite phases in rodents (Hoogerwerf et al., 2007; Sládek et al., 2007; Murakami et al., 2008; Hamdan et al., 2012) . Previous studies comparing rhythmicity between diurnal and nocturnal species reveal that the rhythmic phase of circadian gene expression in the SCN is similar among both species (Mrosovsky et al., 2001; Caldelas et al., 2003; Lambert et al., 2005) , but rhythmicity in the expression of clock genes and clock-controlled genes in the peripheral cells is largely different between nocturnal and diurnal animals (Lambert and Weaver, 2006) . Our present findings in cynomolgus monkeys are also consistent with previous observations.
Although the protein levels of P-gp, MRP2, and BCRP in the intestinal epithelial cells exhibited circadian oscillation, the hepatic expression of these xenobiotic transporters did not show a clear time dependency. In addition to the transcriptional level, circadian oscillation in the expression of proteins is also dependent on translational and/or degradation processes (Yagita et al., 2002; Horiguchi et al., 2013) . The synthesis and stability of P-gp, MRP2, and BCRP proteins in the hepatic cells may be different from those in the intestinal Circadian Expression of the Intestinal P-gp in Monkeys epithelial cells. Further studies are required to clarify these points. The protein levels of CYP3A in the liver and intestinal cells of monkeys showed a large individual variation. In the hepatic and intestinal cells of monkeys, the expression of Cyp3a8 and Cyp3a5 has been identified (Hashizume et al., 2001; Matsunaga et al., 2002) . CYP3A8 exhibits a high homology of amino acid sequence with human CYP3A4. The daily variation in CYP3A4 activity has been suggested by the fact that the pharmacokinetics of several drugs, which are mainly eliminated by CYP3A4 metabolism, vary according to their dosing time (Smith et al., 1986; Min et al., 1997) . Furthermore, after treatment of cultured human hepatic cells with a high concentration serum, the expression of CYP3A4 and its metabolic activity exhibits significant circadian oscillation (Takiguchi et al., 2007) . Although it was unable to clarify the reason for interindividual variation of CYP3A protein levels in monkeys, the hepatic and intestinal expression of CYP3A8 may oscillate in each individual animal. This point should also be clarified in a future study. The PAR bZIP transcription factors HLF, TEF, and DBP have been shown to act as mediators of circadian output physiology. Previous reports suggest that these transcription factors function to control the expression of genes responsible for xenobiotic detoxification (Mrosovsky et al., 2001) . PAR bZIP transcription factors activate the transcription of their target genes through PARRE, whereas E4BP4 acts as a negative regulator of PAR bZIP proteins by competing with each other for the same DNA binding site (Mitsui et al., 2001 ). In the intestinal epithelial cells of mice, HLF and E4BP4 inversely regulates transcription of the Abcb1 gene through the same PARRE (Murakami et al., 2008) . The amino acid sequences of PAR bZip transcription factors exhibit a particular high homology beyond mammalian species (Gachon et al., 2006) , suggesting that they fulfill similar physiologic functions in mammals.
A nucleotide sequence showing homology with PARRE is also located between bp 21628 and 21621, with respect to the translation start site of the cynomolgus monkey Abcb1 gene. In fact, the results of the reporter assay revealed that the PARRE in the cynomolgus monkey Abcb1 gene could respond to PAR bZip transcription factors. Furthermore, the responsiveness of PARRE in the Abcb1 gene to PAR bZip transcription factors was substantially suppressed by E4BP4. The facts suggest that a similar transcriptional mechanism for circadian expression of the Abcb1 gene is conserved in mice and monkeys. Although the oscillation in the intestinal expression of Abcb1 mRNA in monkeys was nearly antiphase to that demonstrated in mice (Murakami et al., 2008) , the rhythmic phase in the expression of P-gp was similar between the two species. The oscillation in the levels of P-gp in the intestinal epithelial cells of monkeys was delayed by approximately 12 hours relative to the Abcb1 mRNA rhythm. The delayed oscillation of the P-gp may be due to the slow kinetics of protein synthesis and/or gradual transportation into the membrane.
Daily variations in the pharmacokinetics of several drugs have been reported in humans (Smith et al., 1986; Min et al., 1997; Erol et al., 2001; Lemmer, 2005) . However, it is difficult to predict the circadian change in the drug pharmacokinetics in diurnal humans by using the data collected from nocturnal animals. In cynomolgus monkeys, the maximum plasma concentrations of P-gp substrates (quinidine and etoposide) after oral administration at 9:00 were significantly higher than those at 21:00. By contrast, there was no significant dosing time-dependent difference in the maximum concentration of a non-P-gp substrate (acetaminophen) after oral administration. The intestinal circadian clock enhanced the expression of P-gp from the late light phase to the early dark phase. Consequently, the intestinal absorption of P-gp substrates in monkeys appeared to be suppressed by administering the drugs at the early dark phase. But there may be some other factors that affect the circadian change in pharmacokinetic profiles of P-gp substrates. A significant dosing time-dependent difference in the pharmacokinetics of digoxin, a typical P-gp substrate, has also been reported in humans (Erol et al., 2001) . A higher serum concentration of digoxin is detected when the drug is administered orally in the morning (8:00). The expression of P-gp in the intestinal cells of humans may exhibit a similar oscillation phase, as demonstrated in monkeys. This study demonstrates that a pharmacokinetic study in monkeys may be a useful way to predict the circadian change in the drug disposition in humans.
The individualization of pharmacotherapy has been mainly achieved by monitoring the drug concentration. Consequently, dosage adjustment has been based on interindividual differences in drug pharmacokinetics; however, intraindividual as well as interindividual variability should be considered for further improving rational pharmacotherapy because the pharmacokinetics of many drugs also vary, depending on the rhythm of absorption, distribution, metabolism, and elimination. Our present findings provide a relationship between the circadian clock and xenobiotic detoxification in monkeys. Evaluation of dosing time dependency of the pharmacokinetics in monkeys would be useful to predict circadian variations of drug disposition in humans. Identification of factors affecting the pharmacokinetics in humans is important to achieve rational pharmacotherapy.
